Dr. Irvine Russell, M.D.
As the Medical Reviewer for Kratom Finder, Dr. Russell ensures every clinical claim about mitragynine pharmacology, 7-hydroxymitragynine risk, drug interactions, and harm-reduction protocol meets rigorous clinical standards.
Credential
Board-Certified Physician
Affiliation
UC Irvine · School of Medicine
Focus
Opioid Pharmacology · Toxicology
Reviews For
Kratom Finder · Kava Finders · ShrooMap · HoneyPackFinder · MadHoneyFinder
Background
Credentials & clinical focus.
Dr. Russell reviews clinical and safety content on Kratom Finder. Board-certified physician with training at UCI School of Medicine and a focus on plant-derived bioactives, pharmacology, toxicology, and nutraceutical safety. Also serves as medical reviewer for ShrooMap, HoneyPackFinder, MadHoneyFinder, and KavaFinders.
Kratom occupies an unusual pharmacological position — pharmacologically an opioid (mu-opioid receptor partial agonist with biased signaling), but legally not scheduled. Dr. Russell's specialty in plant-derived bioactives and opioid pharmacology makes him uniquely positioned to write about the distinctions that matter — leaf vs extract, mitragynine vs 7-OH, dependence profiles, and interaction risks.
Role at Kratom Finder
Four review responsibilities.
Kratom is pharmacologically active, alkaloid content varies widely, and the gap between leaf kratom and isolated 7-OH is under-communicated. Responsible publishing requires physician oversight.
Verifies clinical claims
Every claim about mitragynine pharmacology, 7-OH potency, dependence risk, or drug interactions must map to peer-reviewed evidence.
Scrutinizes brand disclosures
Reviews brands for AKA-GMP certification, lab transparency, and 7-OH labeling. Flags extract and 7-OH concentrate products separately from leaf.
Approves safety language
Writes and signs off on every contraindication, interaction warning, withdrawal protocol, and tapering guideline.
Flags elevated-risk products
Identifies 7-OH concentrates, semi-synthetic derivatives, and extract-kratom-alcohol combinations that carry disproportionate risk.
Areas of Review Expertise
Clinical focus areas.
- → Mitragynine and 7-hydroxymitragynine pharmacology
- → Biased mu-opioid receptor agonism and respiratory-depression ceiling
- → Kratom dependence, withdrawal, and tapering protocols
- → Drug interactions: CYP3A4, CYP2D6, SSRIs, benzos, alcohol, MAOIs
- → Pregnancy contraindications and Neonatal Abstinence Syndrome
- → FDA 7-OH enforcement context and AKA-GMP standards
Editorial independence
No equity.
No brand loyalty.
Dr. Russell is compensated for review time but has no equity interest in Kratom Finder, any indexed brand, or any affiliate partner. If he flags content as medically inaccurate, the content is corrected or removed — regardless of affiliate impact. See our medical review process.
Sister-site review work
Cross-network pharmacology.
Kava Finders
Kavalactone pharmacology, noble-vs-tudei distinction, hepatic safety oversight.
Sister SiteShrooMap
Functional and psychoactive mushroom review — beta-glucan pharmacology, clinical dosing.
Sister SiteMad Honey Finder
Grayanotoxin cardiac safety oversight, bradycardia thresholds, case-literature curation.
Sister SiteHoneyPackFinder
Sildenafil/tadalafil adulteration analysis and PDE5-inhibitor drug-interaction guidance.